Update on the use of etanercept across a spectrum of rheumatoid disorders

Bernard CombeService d&rsquo;Immuno-Rhumatologie, Montpellier, FranceAbstract: Etanercept is a soluble TNF receptor p75 fusion protein which is approved for subcutaneous use (50 mg weekly) in the treatment of patients with active rheumatoid arthritis (RA), juvenile RA, ankylosing spondylitis...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Bernard Combe
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/34d4e5cc2b404c0888c6180605d3f83d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:34d4e5cc2b404c0888c6180605d3f83d
record_format	dspace
spelling	oai:doaj.org-article:34d4e5cc2b404c0888c6180605d3f83d2021-12-02T00:34:46ZUpdate on the use of etanercept across a spectrum of rheumatoid disorders1177-54751177-5491https://doaj.org/article/34d4e5cc2b404c0888c6180605d3f83d2008-06-01T00:00:00Zhttp://www.dovepress.com/update-on-the-use-of-etanercept-across-a-spectrum-of-rheumatoid-disord-a1723https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Bernard CombeService d&rsquo;Immuno-Rhumatologie, Montpellier, FranceAbstract: Etanercept is a soluble TNF receptor p75 fusion protein which is approved for subcutaneous use (50 mg weekly) in the treatment of patients with active rheumatoid arthritis (RA), juvenile RA, ankylosing spondylitis, and psoriatic arthritis. Etanercept binds to both TNF&alpha; and lymphotoxin and has quite a short mean half-life (70 hours). Numerous randomized clinical trials have demonstrated its efficacy to improve signs and symptoms in early and established RA and other inflammatory arthritis. Furthermore, etanercept has shown its ability to prevent radiographic progression and to improve health-related quality of life in patients with RA and psoriatic arthritis. A combination of etanercept plus methotrexate was more efficacious than etanercept monotherapy in RA patients but there is currently no evidence that such rheumatic combination is better than monotherapy in other disorders. Etanercept was generally well tolerated both in controlled trials with withdrawal rates being similar to the comparator groups and in large observational studies. Infections and injection-site reactions were the most frequently reported events. Serious infections were slightly increased but the occurrence of tuberculosis seemed less frequent than with anti-TNF monoclonal antibodies (infliximab and adalimumab). The benefit-risk ratio of etanercept appeared to be very positive, and this drug has now emerged as a major therapy in patients with active inflammatory arthritis. Furthermore, it is more frequently considered as an emerging and valuable option in patients with early disease.Keywords: etanercept, TNF blockers, rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis Bernard CombeDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2008, Iss Issue 2, Pp 165-173 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Bernard Combe Update on the use of etanercept across a spectrum of rheumatoid disorders
description	Bernard CombeService d&rsquo;Immuno-Rhumatologie, Montpellier, FranceAbstract: Etanercept is a soluble TNF receptor p75 fusion protein which is approved for subcutaneous use (50 mg weekly) in the treatment of patients with active rheumatoid arthritis (RA), juvenile RA, ankylosing spondylitis, and psoriatic arthritis. Etanercept binds to both TNF&alpha; and lymphotoxin and has quite a short mean half-life (70 hours). Numerous randomized clinical trials have demonstrated its efficacy to improve signs and symptoms in early and established RA and other inflammatory arthritis. Furthermore, etanercept has shown its ability to prevent radiographic progression and to improve health-related quality of life in patients with RA and psoriatic arthritis. A combination of etanercept plus methotrexate was more efficacious than etanercept monotherapy in RA patients but there is currently no evidence that such rheumatic combination is better than monotherapy in other disorders. Etanercept was generally well tolerated both in controlled trials with withdrawal rates being similar to the comparator groups and in large observational studies. Infections and injection-site reactions were the most frequently reported events. Serious infections were slightly increased but the occurrence of tuberculosis seemed less frequent than with anti-TNF monoclonal antibodies (infliximab and adalimumab). The benefit-risk ratio of etanercept appeared to be very positive, and this drug has now emerged as a major therapy in patients with active inflammatory arthritis. Furthermore, it is more frequently considered as an emerging and valuable option in patients with early disease.Keywords: etanercept, TNF blockers, rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis
format	article
author	Bernard Combe
author_facet	Bernard Combe
author_sort	Bernard Combe
title	Update on the use of etanercept across a spectrum of rheumatoid disorders
title_short	Update on the use of etanercept across a spectrum of rheumatoid disorders
title_full	Update on the use of etanercept across a spectrum of rheumatoid disorders
title_fullStr	Update on the use of etanercept across a spectrum of rheumatoid disorders
title_full_unstemmed	Update on the use of etanercept across a spectrum of rheumatoid disorders
title_sort	update on the use of etanercept across a spectrum of rheumatoid disorders
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/34d4e5cc2b404c0888c6180605d3f83d
work_keys_str_mv	AT bernardcombe updateontheuseofetanerceptacrossaspectrumofrheumatoiddisorders
_version_	1718403607820238848

Update on the use of etanercept across a spectrum of rheumatoid disorders

Ejemplares similares